10.07.19
Leader of Manatt Digital and Technology and the firm’s venture capital / emerging companies practice Lisa Suennen interviewed Vertex Pharmaceutical’s executive vice president of global research and chief scientific officer David Altshuler.
10.06.19
Leader of Manatt Digital and Technology and the venture capital / emerging companies practice Lisa Suennen spoke with CNBC about the launch of Qalytude, an online clinic dedicated to anti-aging.
10.01.19
Manatt Digital and Technology group and venture capital/emerging companies practice leader Lisa Suennen spoke with MM&M Magazine about the gender gap among professionals in the biopharma-marketing industry.
09.23.19
Manatt Digital and Technology leader and leader of the firm’s venture capital / emerging companies practice interviewed FasterCures executive director Tanisha Carino on the latest episode of her podcast Tech Tonics.
09.12.19
Manatt Health senior manager Jared Augenstein spoke with FierceHealthcare on a recently released white paper from Manatt Health that outlines a framework for calculating a telehealth program’s return on investment.
08.25.19
Manatt’s Lisa Suennen, leader of the firm’s digital and technology group, and the firm’s venture capital and emerging companies practice, spoke with MedCity News about digital health companies going public.
07.31.19
Manatt’s Lisa Suennen, leader of the firm’s digital and technology group, spoke with BioPharma Dive about the low number of female CEOs in the biotech industry.
07.09.19
Manatt’s Lisa Suennen, leader of the firm’s digital and technology group and its venture capital fund, spoke with Business Insider about her 13 rules for healthcare entrepreneurs and investors.
07.02.19
Manatt’s Lisa Suennen, leader of the firm’s digital and technology group and the firm’s venture capital / emerging companies practice, spoke with Sharon Gabrielson for her TRUST Podcast about how venture capitalists choose to invest in startups.
06.13.19
Manatt Venture Fund, led by Digital and Technology group leader Lisa Suennen, participated in a $23 million Series B financing for Genome Medical. This brings the company’s total amount of funds raised to $46 million.